### Page 1 of 5 **Spinal Cord Compression Management in Cancer Patients MDAnderson** Cancer Center

Making Cancer History\*

THE UNIVERSITY OF TEXAS

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.





# Spinal Cord Compression Management in Cancer Patients Page 2 of 5

Making Cancer History®

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

<b>APPENDIX A – Frankel Classification</b>			
Grade	Status	Sensory Function below level of compression	Motor Function below Level of Compression
А	Paraplegia	No sensation	Complete paralysis (no function)
В	Sensory function only	Some sensation	Complete paralysis (no function)
С	Nonambulatory		Some motor function, but of no practical use to the patient
D	Ambulatory		Some motor function with some use to the patient
Е	No neurologic signs or symptoms	Normal	Normal

#### Page 3 of 5 **Spinal Cord Compression Management in Cancer Patients MDAnderson** Cancer Center

Making Cancer History"

THE UNIVERSITY OF TEXAS

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.



Reproduced with permission from Bilsky et al, 2010, J Neurosurg: Spine 13(3), 324-328

# Page 4 of 5 Anderson Spinal Cord Compression Management in Cancer Patients

Making Cancer History"

THE UNIVERSITY OF TEXAS

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

## SUGGESTED READINGS

Abrahm JL. (2004). Assessment and treatment of patients with malignant spinal cord compression. J Support Oncol, 2:377-401. Bilsky, M. H., Laufer, I., Rourney, D. R., et al. (2010). Reliability analysis of the epidural spinal cord compression scale. Journal of Neurosurgery: Spine, 13(3), 324-328. Fisher, C. G., Ryken, T. C., Berven, S. H., et al. (2010). A novel classification system for spinal instability in neoplastic disease. Spine 35(22), E1221-E1229. Fourney, D., Frangou, E. M., Ryken, T. C., et al. (2011). Spinal Instability Neoplastic score: an analysis of reliability and validity from the spine oncology study group. Journal of Clinical Oncology, 29(22), 3072-3077. Gilbert RW, Kim JH, Posner JB. (1978). Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 3:40-51 Graham PH, Capp A, Delaney G, et al. (2006). A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.06 superdex study. Clin Oncol. 18:70-76. Greenberg HS, Kim JH, Posner JB. (1980). Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol. 8:361-366 Heimdal K, Hirschberg H, Slettebo H, et al. (1992). High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol. 12:141-144. Kilmo Jr P, Kestle JRW, Schmidt MH. (2003). Treatment of metastatic spinal epidrual disease: a review of the literature. Neurosurg Focus, 15(5):E1 Loblaw DA, Laperriere NJ. (1998). Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol, 16:1613-1624. Loblaw DA, Perry J, Chambers A, et al. (2005). Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the cancer care Ontario practice guidelines initiative's neuro-oncology disease site group. J Clin Oncol, 23(9):2028-2037. Lu C, Gonzalez RG, Jolesz FA, et al. (2005). Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment. J Support Oncol.3:305-312. Penas-Prado M, Loghin ME. (2008). Spinal cord compression in cancer patients: review of diagnosis and treatment. Curr Oncol Rep, 10:78-85. Maranzano E, Latini P, Beneventi S, et al. (1996). Radiotherapy without steroids in selected metastatic spinal cord compression patients: a phase II trial. Am J Clin Oncol. 19(2):179-183. Maranzano E, Latini P, Checcaglini F, et al.. Radiation therapy in metastatic spinal cord compression. Cancer. 67:1311-1317. National Institute for Health and Clinical Excellence. (2008). Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. (Clinical guideline 75.) London: NICE. Posner JB, Howieson J, Cvitkovic E. (1977). "Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. Ann Neurol. 2:409-413. Schmidt MH, Klimo P, Vrionis FD. (2005). Metastatic spinal cord compression. J Natl Compr Canc Netw, 3:711-719. Sorenson PS, Helweg-Larsen S, Mouridsen H, et al. (1994). Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 30A(1):22-27. Vecht CJ, Haaxma-Reiche H, van Putten WLJ, et al. (1989). Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology, 39:1255-1257. Weissman DE. (1988). Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. J Clin Oncol, 6(3):543-551. Yalamanchili M, Lesser GJ. (2003). Malignant spinal cord compression. Curr Treat Options Oncol, 4:509-516



Making Cancer History®

THE UNIVERSITY OF TEXAS

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

## **DEVELOPMENT CREDITS**

This practice consensus algorithm is based on majority expert opinion of the Spinal Cord Compression Work Group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following medical, radiation and surgical oncologists.

> Patricia A. Brock, MD Ashok J. Kumar,  $MD^{\dagger}$ Monica Elena Loghin, MD Anita Mahajan,  $MD^{T}$ Laurence D. Rhines, MD<sup>∓</sup> Terry W. Rice, MD<sup>7</sup> Debra S. Ruiz, RN Komal Shah, MD Claudio Esteves Tatsui, MD Jayne Viets-Upchurch, MD Jeffrey Weinberg, MD

<sup>T</sup> Core Development Team Leads